Trial Profile
Local Monotherapy of REOLYSIN for Patients with Recurrent Malignant Gliomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2015
Price :
$35
*
At a glance
- Drugs Pelareorep (Primary)
- Indications Glioma
- Focus Adverse reactions
- 27 Apr 2015 New trial record
- 17 Apr 2015 According to an Oncolytics Biotech media release, the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for pelareorep [Reolysin], for the treatment of malignant glioma. The Company had applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages.